E
Expansion Therapeutics
A drug discovery and development company pursuing the vast potential of small molecule medicines for RNA-mediated diseases
About Expansion Therapeutics
Expansion Therapeutics, Inc., established in 2016, is a biopharmaceutical company focused on developing orally available, small molecule medicines for severe RNA-mediated diseases. The company was founded by Matthew D. Disney, Ph.D., a professor of chemistry at The Scripps Research Institute, whose laboratory developed the underlying technology. His extensive research into RNA-modifying compounds and the creation of a computational platform to identify druggable RNAs laid the groundwork for the company's scientific approach. This background directly informs the company's mission to create therapies for diseases that currently have no cure. Expansion Therapeutics operates in the biopharmaceutical market, specifically targeting a class of disorders known as expansion repeat disorders, which includes conditions like myotonic dystrophy type 1 (DM1), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and various ataxias. The company's business model is centered on the research and development of a pipeline of proprietary drug candidates. Its primary asset is a platform that enables the design of small molecules capable of binding to RNA structures, a historically challenging target for drug development. By creating oral therapies, the company aims to offer more accessible and convenient treatment options compared to other modalities. The ultimate goal is to move these candidates through clinical trials and eventually commercialize them, generating revenue through drug sales and potential licensing partnerships with larger pharmaceutical firms. To date, Expansion Therapeutics has secured significant financial backing to advance its research. The company raised $55.3 million in a Series A financing round and later completed an $80 million Series B financing round in 2021, with participants including Cormorant Asset Management, RA Capital Management, and Novartis Venture Fund, among others. This capital is being deployed to progress its portfolio of RNA-targeted small molecules for multiple neurological diseases into clinical development.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2021 | $80M | $320M | Kleiner Perkins · 5AM Ventures · Cormorant Asset Management · RA Capital Management | — |
| SERIES AOther financing | Jan 2018 | $55M | $221M | Alexandria Venture Investments · RA Capital Management · Sanofi-Genzyme BioVentures · Novartis Venture Fund | — |
Growth signals
Latest recorded traffic for Expansion Therapeutics is 580 monthly website visits, down 58.6% over the last three months. Expansion Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Expansion Therapeutics in the Jupiter ecosystem
The Expansion Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A11 investors entered at this stage
Kleiner Perkins
5AM Ventures
Alexandria Venture Investments
RA Capital Management
Sanofi-Genzyme BioVentures
Novartis Venture Fund
Cormorant Asset Management
Sanofi Ventures
Westlake Village BioPartners
Logos Capital
Surveyor Capital
Other known investors1 additional known investor
Scripps Translational Science Institute
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Expansion Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Expansion Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









